Clinical Trials Browser

Phase 1/2 × enfortumab vedotin × 90 days × Clear all

NCT07232602 2026-03-16

MK-3475-04D

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

Advanced Bladder Cancer

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell